Advertisement

PharmacoEconomics

, Volume 19, Issue 10, pp 973–982 | Cite as

Formulary Restriction of Selective Serotonin Reuptake Inhibitors for Depression

Potential Pitfalls
  • Paula L. Hensley
  • H. George Nurnberg
Current Opinion

Abstract

The American healthcare market is currently estimated at more than $US900 billion with double digit rising costs per year. Psychotropic agent costs have more than kept pace with market increases. Medication acquisition costs are an obvious focus for limiting costs in various care systems.

Restrictive formularies are a common method of attempting to limit costs. To support our opinion that a single agent is ill advised, we explored the available evidence on the intended and unintended consequences of having a single or exclusive selective serotonin reuptake inhibitor (SSRI) on a formulary. Central to this position is an assumption of the interchangeability of SSRIs; we examined the evidence for and against this through a model to determine the probability of interchangeability. We conclude that the practice of having a single SSRI on the formulary for a healthcare plan seems ill founded. Patients who switch antidepressants remain in treatment 50% longer and cost approximately 50% more to treat in a more costly treatment setting.

Giving the primary care physician several antidepressant choices can provide more options to continue treatment of his or her patient in the less expensive primary care setting. In terms of cost containment, formulary restrictions are far more likely to have the opposite effect.

Keywords

Fluoxetine Paroxetine Selective Serotonin Reuptake Inhibitor Antidepressant Medication Health Maintenance Organisation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993 Nov; 54 (11): 405–18PubMedGoogle Scholar
  2. 2.
    Narrow WE. One-year prevalence of depressive disorders among adults 18 and over in the US. NIMH ECA prospective data. Population estimates based on U.S. Census estimated residential population age 18 and over on July 1, 1998 (reprinted from http://www.nimh.nih.gov/publicat/numbers.cfm#1)
  3. 3.
    Kohl M. Maelstrom in Michigan over medication. Mental Health Economics Supplement to Psychiatric Times 2000 Mar: 6–7Google Scholar
  4. 4.
    Guze BH. Selective serotonin reuptake inhibitors: assessment for formulary inclusion. Pharmacoeconomics 1996 May; 9(5): 430–42PubMedCrossRefGoogle Scholar
  5. 5.
    Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897–902PubMedCrossRefGoogle Scholar
  6. 6.
    McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990 Jun; 51 (6 Suppl.): 60–9PubMedGoogle Scholar
  7. 7.
    Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–73PubMedCrossRefGoogle Scholar
  8. 8.
    Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331(10): 650–5PubMedCrossRefGoogle Scholar
  9. 9.
    Dunn RL, Donoghue JM, Ozminkowski RJ, et al. Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol 1999; 13(2): 136–43PubMedCrossRefGoogle Scholar
  10. 10.
    Alchin TM, Tranby HW. Who bears the cost of antidepressant in Australia? Med J Aust 1994 Nov 7; 161: 547–9Google Scholar
  11. 11.
    Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part II. The cost-effectiveness of SSRIs in treatment of depression. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997Google Scholar
  12. 12.
    Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996; 53: 777–84PubMedCrossRefGoogle Scholar
  13. 13.
    Montgomery SA, Brown RE, Clark M. Economic analysis of treating depression with nefazodone v. imipramine. Br J Psychiatry 1996; 168: 768–71PubMedCrossRefGoogle Scholar
  14. 14.
    McFarland BH. Cost-effectiveness considerations for managed care systems: treating depression in primary care. Am J Med 1994; 97(6A): 47–58SCrossRefGoogle Scholar
  15. 15.
    LaPierre Y, Bentkover J, Schainbaum S, et al. Direct cost of depression: analysis of treatment costs of fluoxetine versus imipramine in Canada. Can J Psychiatry 1995; 40: 370–7PubMedGoogle Scholar
  16. 16.
    Mitchell J, Greenberg J, Finch K, et al. Effectiveness and economic impact of antidepressant medications: a review. Am J Man Care 1997; 3: 323–30Google Scholar
  17. 17.
    DeWilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressant patients. Acta Psychiatr Scand 1993; 87: 141–5CrossRefGoogle Scholar
  18. 18.
    Gregor KJ, Overhage J, Coons SJ, et al. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clin Ther 1994; 16: 306–15PubMedGoogle Scholar
  19. 19.
    Hylan TR, Neslusan CA, Baldridge RM, et al. SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. J Clin Outcome Measures 1997; 4: 16–22Google Scholar
  20. 20.
    Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Man Care 1996; 2: 1239–46Google Scholar
  21. 21.
    Zanardi R, Franchini L, Gasperini M, et al. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996; 153: 1631–3PubMedGoogle Scholar
  22. 22.
    Depression Guideline Panel. Depression in primary care. Vol. 2 Treatment of major depression. Rockville (MD): US Department of Health and Human Studies, 1993 (Agency for Health Care Policy and Research Publication 93-0551)Google Scholar
  23. 23.
    Kasper S, Heiden A. Do SSRIs differ in their antidepressant efficacy? Hum Psychopharmacol 1995; 10: S163–72CrossRefGoogle Scholar
  24. 24.
    Ereshefsky L. Antidepressants: a pharmacologic rationale for treatment and product selection. Formulary 1995; 30 (1 Suppl.): S10–9Google Scholar
  25. 25.
    Streja DA, Hui RL, Streja E, et al. Selective contacting and patient outcomes: a case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants. Am J Man Care 1999 Sept; 5 (9): 1133–42Google Scholar
  26. 26.
    Horn SD, Sharkey PD, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: results from the managed care outcomes project. Am J Man Care 1996 Mar; 11 (3): 253–64Google Scholar
  27. 27.
    Horn SD, Sharkey PD, Gassaway J. Managed Care Outcomes Project: study design, baseline patient characteristics, and outcome measures. Am J Manage Care 1996; 2: 237–47.Google Scholar
  28. 28.
    Ross-Degnan D, Soumerai SB. HMO formularies and care costs [letter]. Lancet 1996 May 4; 347: 1264Google Scholar
  29. 29.
    Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 1999 Sept; 60 (9): 574–9PubMedCrossRefGoogle Scholar
  30. 30.
    Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997; 170: 120–7PubMedCrossRefGoogle Scholar
  31. 31.
    Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br J Psychiatry 1995; 310: 1433–8Google Scholar
  32. 32.
    Joffe RT, Levitt AJ, Sokolov STH, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996; 57: 114–5PubMedGoogle Scholar
  33. 33.
    Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58: 16–21PubMedCrossRefGoogle Scholar
  34. 34.
    Brown WA, Harrison W. Are patients who are intolerant to one serotonin reuptake inhibitor intolerant to another? J Clin Psychiatry 1995; 56: 30–4PubMedGoogle Scholar
  35. 35.
    Nurnberg HG, Lauriello J, Hensley PL, et al. Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients. J Clin Psychiatry 1999; 60: 33–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Department of Psychiatry, School of MedicineUniversity of New Mexico Health Sciences CenterAlbuquerqueUSA
  2. 2.UNM Mental Health CenterUniversity of New Mexico Health Sciences CenterAlbuquerqueUSA

Personalised recommendations